Hanson Kristopher
Known title: General CounselCIK: 0001789970
Associated companies
Transaction History
| MPLT | ▼ Sell | Open Market | 16,509 | $193K | 9/16/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 7,730 | $0 | 8/17/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 1,130 | $43K | 7/17/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 4,776 | $174K | 7/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 3,331 | $124K | 7/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 11 | $418 | 7/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 2,147 | $77K | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 5,103 | $189K | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 10 | $375 | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 284 | $8K | 5/11/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 846 | $24K | 5/11/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 6,979 | $210K | 5/11/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 5,808 | $177K | 5/11/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 9,030 | $248K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 3,908 | $111K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 296 | $9K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 683 | $21K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 73 | $2K | 4/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 225 | $6K | 4/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 1,529 | $41K | 4/15/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 7,730 | $0 | 2/5/2026 | View on chart |
| MPLT | ▼ Sell | Tax Withholding | 26,007 | $468K | 1/27/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 27,098 | $0 | 10/27/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MapLight Therapeutics Shares Fall 34.8% in Four Weeks
MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.
MapLight Therapeutics Shares Fall 34.8% in Four Weeks. MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.